Increased fatty acid oxidation (null)

"Increased fatty acid oxidation through metabolic switching" is not a single molecule or receptor but rather describes a cellular metabolic state or process. This process involves the upregulation of mitochondrial β‐oxidation pathways that break down long-chain fatty acids into acetyl-CoA for energy production. The switch from glucose metabolism to increased reliance on fatty acids typically occurs during periods of low glucose availability or increased energy demand. Key molecular regulators include the protein deacetylase SIRT1 and the transcriptional coactivator PGC‐1α. Under low-glucose conditions, rising NAD+ levels activate SIRT1, which then deacetylates PGC‐1α. This leads to increased expression of genes encoding enzymes such as carnitine palmitoyltransferases (CPTs) and medium-chain acyl-CoA dehydrogenase (MCAD), all essential for efficient mitochondrial uptake and breakdown of long-chain fatty acids[5][7]. Pyruvate dehydrogenase kinase 4 (PDK4) also plays a role by inhibiting pyruvate entry into the TCA cycle, further favoring fat over carbohydrate use as an energy source[5]. This metabolic adaptation is crucial in tissues with high-energy demands like heart muscle but can be dysregulated in diseases such as heart failure or insulin resistance syndromes[7]. While drugs may target individual enzymes or regulatory proteins within this pathway—such as AMPK activators or SIRT1 modulators—there are no drugs that directly target "increased fatty acid oxidation through metabolic switching" itself because it is not a discrete molecular entity. Summary: The phrase refers to a physiological process regulated by multiple proteins/enzymes rather than a canonical druggable target; thus it should not be considered an individual therapeutic target according to standard nomenclature conventions.[2][3][5][7]

Other names

Metabolic switching to fatty acid oxidationEnhanced fatty acid β-oxidationFAO upregulation

Activation of transcriptional regulators (e.g., SIRT1, PGC‐1α) that induce expression of genes involved in mitochondrial and fatty acid oxidation[5][7]; Inhibition of pyruvate dehydrogenase kinase 4 (PDK4), shifting substrate utilization from glucose to fatty acids[5]